U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Insulin glargine, a long-acting form of insulin, was marketed under the brand name LANTUS. Lantus is indicated for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. The primary activity of insulin glargine is regulation of glucose metabolism. It lowers blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. The off-label use of insulin glargine is the treatment type 2 diabetes in children and the treatment of gestational diabetes.

Approval Year

2000
157
Targets

Targets

Primary TargetPharmacologyConditionPotency
Insulin receptor
12
Target ID: P06213
Gene ID: 3643.0
Gene Symbol: INSR
Target Organism: Homo sapiens (Human)
Agonist
2470
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8043
LANTUS

Approved Use

LANTUS is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Launch Date

9.5610241E11
Primary
Approved
8043
LANTUS

Approved Use

LANTUS is indicated for once-daily subcutaneous administration at bedtime in the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Launch Date

9.5601597E11
PubMed

PubMed

TitleDatePubMed
Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel.
2014 Apr

Sample Use Guides

In Vivo Use Guide
LANTUS (Insulin glargine) should be administered subcutaneously once a day at bedtime. LANTUS is not intended for intravenous administration.
Route of Administration: Other
Substance Class Protein
Created
by admin
on Fri Jun 25 21:06:15 UTC 2021
Edited
by admin
on Fri Jun 25 21:06:15 UTC 2021
Protein Sub Type
Sequence Type COMPLETE
Record UNII
2ZM8CX04RZ
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
INSULIN GLARGINE
EMA EPAR   INN   MI   USAN   USP-RS   WHO-DD  
USAN   INN  
Official Name English
INSULIN GLARGINE [EMA EPAR]
Common Name English
INSULIN,GLARGINE,HUMAN/RDNA [VANDF]
Common Name English
TOUJEO SOLOSTAR
Brand Name English
INSULIN GLARGINE RECOMBINANT [ORANGE BOOK]
Common Name English
BASAGLAR COMPONENT INSULIN GLARGINE
Brand Name English
INSULIN (HUMAN), 21A-GLYCINE-30BA-L-ARGININE-30BB-L-ARGININE-
Common Name English
LANTUS R
Brand Name English
INSULIN GLARGINE COMPONENT OF SOLIQUA 100/33
Brand Name English
GLARGIN
Common Name English
INSULIN GLARGINE [WHO-DD]
Common Name English
HOE 901
Code English
INSULIN,GLARGINE,HUMAN/RDNA
VANDF  
Common Name English
INSULIN GLARGINE COMPONENT OF BASAGLAR
Brand Name English
INSULIN GLARGINE [INN]
Common Name English
INSULIN GLARGINE [USAN]
Common Name English
LUSDUNA
Brand Name English
HOE-71GT
Code English
INSULIN GLARGINE [USP-RS]
Common Name English
HOE-901
Code English
INSULIN (A20A-GLYCINE,B30A-ARGININE,B30B-ARGININE) (HUMAN)
Common Name English
LY-2963016
Code English
LY2963016
Code English
SOLIQUA 100/33 COMPONENT INSULIN GLARGINE
Brand Name English
GLARGINE
Common Name English
INSULIN GLARGINE [MI]
Common Name English
INSULIN GLARGINE [USP MONOGRAPH]
Common Name English
MK-1293
Code English
INSULIN GLARGINE RECOMBINANT
ORANGE BOOK  
Common Name English
HOE 71GT
Code English
INSULIN GLARGINE [EP MONOGRAPH]
Common Name English
INSULIN (A21-GLYCINE,B31-ARGININE,B32-ARGININE) (HUMAN)
Common Name English
LANTUS
Brand Name English
BASAGLAR
Brand Name English
Classification Tree Code System Code
NDF-RT N0000175453
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
WHO-ATC A10AE54
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
NDF-RT N0000004931
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
NDF-RT N0000004931
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
WHO-ATC A10AE04
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
NDF-RT N0000004931
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
WHO-VATC QA10AE04
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
Code System Code Type Description
MESH
C106526
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
PRIMARY
EPA CompTox
160337-95-1
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
PRIMARY
WIKIPEDIA
INSULIN GLARGINE
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
PRIMARY
EVMPD
SUB08196MIG
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
PRIMARY
FDA UNII
2ZM8CX04RZ
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
PRIMARY
IUPHAR
7572
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
PRIMARY
INN
7548
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
PRIMARY
CAS
160337-95-1
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
PRIMARY
RXCUI
274783
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
4901
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
PRIMARY
ChEMBL
CHEMBL1201497
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
PRIMARY
MERCK INDEX
M6297
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
PRIMARY Merck Index
PUBCHEM
118984454
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
PRIMARY
NCI_THESAURUS
C47564
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
PRIMARY
DRUG BANK
DB00047
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
PRIMARY
USP_CATALOG
1342059
Created by admin on Fri Jun 25 21:06:15 UTC 2021 , Edited by admin on Fri Jun 25 21:06:15 UTC 2021
PRIMARY USP-RS
From To
1_7 2_7
1_19 2_20
2_6 2_11
Related Record Type Details
INSULIN GLARGINE BIOSIMILAR-BIOCON
BIOSIMILAR -> PARENT
INSULIN RECEPTOR
TARGET -> AGONIST
INSULIN GLARGINE BIOSIMILAR - GAN & LEE PHARMACEUTICALS
SUB_CONCEPT->SUBSTANCE
INSULIN GLARGINE BIOSIMILAR - GAN & LEE PHARMACEUTICALS
BIOSIMILAR -> PARENT
INSULIN GLARGINE BIOSIMILAR-BIOCON
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
INSULIN GLARGINE
ACTIVE MOIETY
INSULIN GLARGINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966